vimarsana.com

Latest Breaking News On - Elizabethhz thompson - Page 4 : vimarsana.com

Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)

At Week 24, patients treated with TEPEZZA achieved a 2.41 mm reduction in proptosis from baseline compared with 0.92 mm for those receiving placebo 62% of patients treated with TEPEZZA had. | April 10, 2023

Phase 4 Trial Reports Positive Data on Teprotumumab for Thyroid Eye Disease

Announced today by Horizon Therapeutics, the positive and statistically significant data supports the efficacy of teprotumumab across a spectrum of patients with TED regardless of disease activity or duration.

Tepezza Improves Proptosis in Patients With Chronic Thyroid Eye Disease

Tepezza (teprotumumab-trbw) significantly reduced proptosis in adults with chronic thyroid eye disease and chronic/low clinical activity score.

Dazodalibep improves disease activity, symptoms in two Sjögren s syndrome populations

Dazodalibep has successfully improved disease activity and symptoms two patient populations with Sjögren’s syndrome in a phase 2 trial, according to a press release from Horizon Therapeutics. The company added that dazodalibep (VIB4920, Horizon), a CD40 ligand antagonist, is currently the only drug in development to achieve the primary endpoint in these populations in a phase 2 trial.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.